Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated ...

30% had de novo diffuse large B-cell lymphoma, 17% had low-grade follicular lymphoma, 8% had transformed indolent non-Hodgkin lymphoma or grade 3B follicular lymphoma, 6% had high-grade B-cell ...

A phase 1 clinical trial co-led by researchers at Washington University School of Medicine in St. Louis found that a new type ...

Panelists discuss key factors in deciding between monotherapy and combination approaches for bispecific therapies in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) as well as the ...

Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings ...

AT-19 is under clinical development by Shanghai YaKe Biotechnology and currently in Phase II for Diffuse Large B-Cell Lymphoma.

They are generally classified according to the cancer's growth rate as high grade (fast growing ... of genetic subtypes in diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS ...

Bristol Myers Squibb Canada (BMS) is pleased to announce Health Canada's approval of Breyanzi® (lisocabtagene maraleucel), a type of chimeric antigen receptor T cell (CAR T) therapy, for the treatment ...

The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

SGR-1505 is under clinical development by Schrodinger and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have a 78% phase transition ...